Oral Edaravone Dosing Intervals for Meal-Stable Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Edaravone, currently available only as an injectable agent, faces challenges in oral administration due to meal-related pharmacokinetic variations, necessitating a method to stabilize its absorption and distribution.
Innovation Solution
Administering edaravone orally or intragastrically with specific time intervals after meals, such as 8 hours after a high-fat meal, 4 hours after a standard meal, or 2 hours after a light meal, to minimize meal effects on its pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If edaravone is administered orally without specific timing constraints, then ease of administration is improved, but pharmacokinetic stability deteriorates due to meal-related variations
Solution Approach 1:
The patent applies parameter changes by establishing specific time interval parameters between meal consumption and edaravone administration. Different time intervals are specified based on meal type: 8 hours or longer after high-fat meals, 4 hours or longer after standard meals, and 2 hours or longer after light meals. This parameter-based approach allows the administration guidelines to adapt to varying meal compositions while maintaining pharmacokinetic stability.
2Productivity
If edaravone is administered immediately after meals, then patient compliance is improved, but absorption consistency deteriorates
Solution Approach 1:
The patent applies preliminary action by requiring patients to fast for a predetermined time interval before administering edaravone. This preliminary fasting period allows the gastrointestinal tract to return to a baseline state, ensuring consistent absorption conditions. The required fasting period is determined in advance based on meal type, allowing patients to plan accordingly while maintaining absorption consistency.
3Stability of the object's composition
If strict fasting requirements are imposed before edaravone administration, then pharmacokinetic stability is improved, but ease of operation deteriorates
Solution Approach 1:
The patent applies dynamics by making the fasting requirement flexible rather than fixed. The required fasting time interval varies dynamically based on the type of meal consumed: 8 hours or longer for high-fat meals, 4 hours or longer for standard meals, and 2 hours or longer for light meals. This dynamic approach allows the fasting requirement to adapt to the patient's actual meal pattern, balancing pharmacokinetic stability with ease of administration.
Data Source
AI summary
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.